Observational studySurgical endoscopy2022
PuraStat in gastrointestinal bleeding: results of a prospective multicentre observational pilot study.
Observational study in Surgical endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06698419 (A Prospective Study), which is not on this map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Study: The Effect of RADA16 on Mastoid Cavity Epithelialization After Canal Wall Down Mastoidectomy
Who cites it
51 citing papers in PubMed.
- Trial
- Review
- Use of the self-assembling peptide (PuraStat™) for the management and prevention of ERCP-related bleeding: a multicenter prospective cohort study.Surgical endoscopy · 2026Observational
- Endoscopic ultrasound-guided angioembolization using cyanoacrylate for management of refractory non-variceal upper gastrointestinal bleeding.Surgical endoscopy · 2026Article
- Efficacy and safety of PuraStatSurgery today · 2026Article
- From Biomaterial Innovation to Surgical Practice: A Systematic Review of RADA16 Self-Assembling Peptide Hydrogel in Otolaryngology and Head & Neck Surgery.Journal of clinical medicine · 2026Review
- Endoscopic Management of Malignancy-Related Gastrointestinal Bleeding: A Comprehensive Narrative Review.Medical sciences (Basel, Switzerland) · 2026Review
- Use of a Novel Self-assembling Peptide Gel for Prevention of Bleeding After Endoscopic Mucosal Resection of Large Nonpedunculated Sessile Colorectal Polyps: A Case-Control Study.Gastro hep advances · 2026Article
- Effect of a self-assembling peptide hydrogel on delayed bleeding following endoscopic sphincterotomy: Prospective pilot cohort study.Endoscopy international open · 2026Article
- In Situ Photoactivated Hydrogel Adhesive Dressings for Post Colon Polypectomies (PolypCures).bioRxiv : the preprint server for biology · 2025Article
- Hemostasis achieved with new self-assembling peptide hemostatic gel for a bleeding duodenal diverticulum.Endoscopy · 2025Article
- Successful hemostasis of spurting gastric ulcer bleeding using self-assembling peptide gel.Endoscopy · 2025Article
- Nasal RADA16 hydrogel application decreases epistaxis severity scores in adults with hereditary hemorrhagic telangiectasia.Blood vessels, thrombosis & hemostasis · 2025Article
- RADA-16 Reduces Postoperative Epistaxis After Inferior Turbinate Submucosal Resection.The Laryngoscope · 2025Article
- Review
- Article
- Use of the Slow-Delivery Platform, VacSIM, Shapes the Host Immune Response to Increase Protection Against Influenza Infection.Viruses · 2025Article
- Endoscopic Therapy for Anastomotic Bleeding in Inflammatory Bowel Disease.Digestive diseases and sciences · 2025Review
- Hemostasis: Role of PuraStatWorld journal of gastrointestinal endoscopy · 2025Article
- Effective management of refractory haematuria using PuraStat: A case report and literature review.Urology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA recently developed haemostatic peptide gel for endoscopic application has been introduced to improve the management of gastrointestinal bleeding. The aim of this pilot study was to evaluate the feasibility, safety, efficacy and indication profiles of PuraStat in a clinical setting.
methodsIn this prospective observational multicentre pilot study, patients with acute non-variceal gastrointestinal bleeding (upper and lower) were included. Primary and secondary application of PuraStat was evaluated. Haemoglobin, prothrombin time, platelets and transfusion behaviour were documented before and after haemostasis. The efficacy of PuraStat was assessed during the procedure, at 3 days and 1 week after application.
results111 patients with acute gastrointestinal bleeding were recruited into the study. 70 percent (78/111) of the patients had upper gastrointestinal bleeding and 30% (33/111) had lower gastrointestinal bleeding. After primary application of PuraStat, initial haemostatic success was achieved in 94% of patients (74/79, 95% CI 88-99%), and in 75% of the patients when used as a secondary haemostatic product, following failure of established techniques (24/32, 95% CI 59-91%). The therapeutic success rates (absence of rebleeding) after 3 and 7 days were 91% and 87% after primary use, and 87% and 81% in all study patients. Overall rebleeding rate at 30 day follow-up was 16% (18/111). In the 5 patients who finally required surgery (4.5%), PuraStat allowed temporary haemostasis and stabilisation.
conclusionsPuraStat expanded the therapeutic toolbox available for an effective treatment of gastrointestinal bleeding sources. It could be safely applied and administered without complications as a primary or secondary therapy. PuraStat may additionally serve as a bridge to surgery in order to achieve temporary haemostasis in case of refractory severe bleeding, possibly playing a role in preventing immediate emergency surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.